Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene ...

Q4 2024 Management View CEO Krish Krishnan highlighted 2024 as a strong year, driven by the continued success of the VYJUVEK launch in the U.S., which is tracking as a top-tier rare disease launch. He ...

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 billion and an impressive 180% stock return over the past year, announced that ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into phase 2. The Waltham, Massachusetts-based company already unveiled ...

Japanese culture offers numerous habits for a balanced lifestyle. By borrowing these simple yet effective habits from Japanese culture, anyone can improve their relationship with food and prevent ...

Travel to Japan has never been more popular. Yet, while the country has an enviable amount of assets, most tourists only visit perennial favorites like Tokyo, Osaka and Kyoto and miss out on the ...

The return of inflation and wage growth is giving the Bank of Japan room to raise interest rates and declare the end of a long period of stagnation. Source: FactSet, Bank of Japan By The New York ...